Financial reports
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
5 Mar 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
10-K
2017 FY
Annual report
16 Feb 18
10-Q
2017 Q3
Quarterly report
9 Nov 17
10-Q
2017 Q2
Quarterly report
14 Aug 17
Current reports
8-K
Termination of a Material Definitive Agreement
12 Nov 19
8-K
Entry into a Material Definitive Agreement
3 Oct 19
8-K
Other Events
30 Sep 19
8-K
Dova Pharmaceuticals Reports Second Quarter 2019
6 Aug 19
8-K
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication
27 Jun 19
8-K
Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results
7 May 19
8-K
Submission of Matters to a Vote of Security Holders
26 Apr 19
8-K
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
5 Mar 19
8-K
Departure of Directors or Certain Officers
8 Feb 19
8-K
Regulation FD Disclosure
7 Jan 19
Registration and prospectus
15-12B
Securities registration termination
22 Nov 19
25-NSE
Exchange delisting
12 Nov 19
POS AM
Prospectus update (post-effective amendment)
12 Nov 19
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Nov 19
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Nov 19
SC 14D9/A
Tender offer solicitation (amended)
12 Nov 19
SC TO-T/A
Third party tender offer statement (amended)
12 Nov 19
SC TO-T/A
Third party tender offer statement (amended)
1 Nov 19
SC 14D9/A
Tender offer solicitation (amended)
1 Nov 19
SC 14D9
Tender offer solicitation
11 Oct 19
Other
EFFECT
Notice of effectiveness
19 Nov 19
CT ORDER
Confidential treatment order
14 Dec 18
CT ORDER
Confidential treatment order
7 Sep 18
EFFECT
Notice of effectiveness
9 Aug 18
CORRESP
Correspondence with SEC
6 Aug 18
UPLOAD
Letter from SEC
6 Aug 18
EFFECT
Notice of effectiveness
22 Feb 18
CORRESP
Correspondence with SEC
20 Feb 18
CORRESP
Correspondence with SEC
20 Feb 18
UPLOAD
Letter from SEC
1 Feb 18